Navigation Links
OXIS International Assumes Control and Exploitation Rights to Key L-Ergothioneine Patent Filing Representing a Major Market Opportunity
Date:6/30/2010

BEVERLY HILLS, Calif., June 30 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI), is extremely pleased to announce that it has assumed control and future exploitation rights to International Patent PCT Application PCY/US2008/059831. The invention centers on the use of L-Ergothioneine ("ERGO") as a primary preservative for cells and tissue in culture. Such preservatives are essential for keeping cells in their "normal" state for later use or study and for transporting cells without damage.  Today, freezing is the primary method for cell preservation.  But freezing often compromises the recovery and/or normal function of the cells.  One of the many practical applications of this improved method of preservation is for artificial insemination, where the ability to more easily preserve, transport and use sperm cells without alteration offers many advantages. This offers significant value if the sperm can be preserved and kept viable for extended periods time. ERGO has been shown to be highly effective as a cellular preservative, not only for cells and tissue but organs as well.  In that regard, ERGO may well offer a further future opportunity as a preservative for transplant organs. OXIS and its active scientific board will continue to research and deliver important and practical new applications for ERGO that represent significant market opportunities for the Company. "This patent filing reinforces the efficacy and market opportunity approach OXIS is currently taking with this breakthrough antioxidant," added Tony Cataldo, CEO.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage fro
'/>"/>

SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... REDMOND, Washington , 29. Juli 2015 ... deutschen Diabeteszentrums wurde festgestellt, dass die tägliche ... von Nutraceutix die menschliche Darmflora anreichert und ... Insulinsekretion erhöhen. Die Studie umfasste die tägliche ... (ATCC-Stamm SD-5865) in Tablettenform unter Verwendung der ...
(Date:7/29/2015)... 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ) ... interest assignment agreement (the "Agreement") in which it has ... ) with up to $200 million in revenue interest ... of Iclusig ® (ponatinib).  Funding of the first ... $50 million each, with the initial amount having already ...
(Date:7/29/2015)... Touro College has announced that it is supporting ... of five media marijuana licenses to be issued by the ... (DOH).  If CanniCare is selected, Touro would ... "Our college is supportive of medicinal development and research," ... College System. "There is still a great deal of research ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Touro College Announces Support for CanniCare's Medical Cannabis License Application 2
... 2011 Curemark, LLC , ( www.curemark.com ), a ... neurological diseases, announced that the company has completed its targeted ... its autism treatment. Curemark has reached its targeted ... are participating in the CM-AT Phase III trial at 18 ...
... 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, today announced results for the year ... 10-K is available through Echo,s website at www.echotx.com ...
Cached Medicine Technology:Curemark Completes Enrollment of Phase III Autism Trials 2Echo Therapeutics Announces 2010 Financial Results 2Echo Therapeutics Announces 2010 Financial Results 3Echo Therapeutics Announces 2010 Financial Results 4
(Date:7/29/2015)... ... July 29, 2015 , ... ... that Columbia University Medical Center, located in New York, NY, selected the ReadyCam ... easy for physicians and scientists to immediately access worldwide TV and cable news ...
(Date:7/29/2015)... ... July 29, 2015 , ... Abt Associates has named ... Health division. In her position, Ramkeesoon will help build and expand work ... Ramkeesoon spent close to a decade at ICF International, most recently as a ...
(Date:7/29/2015)... ... 29, 2015 , ... Andrzej Klos, M.D., has been reviewed and approved as ... 38 years, is motivated each and every day by his sincere desire to help ... his many awards and accolades, which include multiple listings in many highly regarded medical ...
(Date:7/29/2015)... ... 29, 2015 , ... Today the nonprofit Alliance for ... Vaccination in Older Adults, that provides a comprehensive overview of the factors that ... health care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, and ...
(Date:7/29/2015)... ... , ... " Core Organizer ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... help anyone get organized. , Wouldn’t it be great if everyone could be a ...
Breaking Medicine News(10 mins):Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Get More Organized with the Core Organizer App 2
... Health and the University of Colorado Denver have discovered a ... acute lung injury. Acute lung injury (ALI) is often caused ... in the blood, and fluid in the lungs. It is ... afflicting almost 200,000 people in the United States each year, ...
... Pharos Innovations, a pioneer in,assisting clients to ... a device-free remote monitoring platform,today announced it is ... of two key appointments in medical informatics and ... http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO ) , ...
... N.Y., Jan. 16 Bausch & Lomb, the ... Valenti, III, will join Bausch & Lomb as ... month."Pete possesses deep leadership experience, as well as ... Stuart Heap, corporate vice president and global president, ...
... 16 /PRNewswire-FirstCall/ - Thomas E. Gardner, Chairman, announced ... appointed to the NUCRYST Pharmaceuticals, Board of Directors. ... Executive Officer of The Westaim Corporation ("Westaim"), NUCRYST,s ... common shares. Prior to his appointment as President ...
... 16 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced updates on ... and international markets in,2009. , ... of ten products, achieving the goals,for new product ...
... in Guangdong ProvincePROVO, Utah, Jan. 15 Nu Skin ... that it has received official notification from the Chinese ... selling activities in four cities in the Guangdong province ... Skin Enterprises the opportunity to offer a direct selling ...
Cached Medicine News:Health News:Gene associated with reduced mortality from acute lung injury 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 3Health News:Bausch & Lomb Names Peter Valenti, III, as President, North America, Vision Care 2Health News:NUCRYST Pharmaceuticals appoints a new director 2Health News:NUCRYST Pharmaceuticals appoints a new director 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 2Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 4Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 5Health News:Nu Skin Enterprises Receives Broader Direct Selling Authorization in China 2
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: